HC Wainwright Has Bearish Estimate for TARS Q3 Earnings

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Stock analysts at HC Wainwright decreased their Q3 2026 earnings estimates for shares of Tarsus Pharmaceuticals in a research report issued to clients and investors on Friday, August 7th. HC Wainwright analyst M. Caufield now expects that the company will post earnings per share of ($1.50) for the quarter, down from their prior estimate of ($0.17). HC Wainwright has a “Buy” rating and a $88.00 price target on the stock. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($1.45) per share. HC Wainwright also issued estimates for Tarsus Pharmaceuticals’ Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($2.25) EPS, FY2027 earnings at $0.93 EPS, FY2028 earnings at $2.27 EPS, FY2029 earnings at $3.23 EPS and FY2030 earnings at $4.61 EPS.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.24). The firm had revenue of $173.91 million for the quarter, compared to analysts’ expectations of $169.65 million. Tarsus Pharmaceuticals had a negative return on equity of 13.53% and a negative net margin of 7.67%.

Other research analysts also recently issued research reports about the company. Wall Street Zen downgraded Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Mizuho dropped their price objective on Tarsus Pharmaceuticals from $100.00 to $98.00 and set an “outperform” rating on the stock in a report on Friday, July 31st. Guggenheim cut their target price on Tarsus Pharmaceuticals from $90.00 to $89.00 and set a “buy” rating on the stock in a research report on Tuesday, July 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Friday, July 17th. Finally, Oppenheimer started coverage on shares of Tarsus Pharmaceuticals in a research report on Friday, April 24th. They set an “outperform” rating and a $98.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Tarsus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $90.17.

Tarsus Pharmaceuticals Stock Up 4.6%

Shares of Tarsus Pharmaceuticals stock opened at $67.76 on Tuesday. Tarsus Pharmaceuticals has a 1-year low of $47.60 and a 1-year high of $85.25. The company has a market capitalization of $2.97 billion, a PE ratio of -62.16 and a beta of 0.53. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.20 and a quick ratio of 3.17. The business has a 50-day moving average of $61.57 and a 200-day moving average of $64.87.

Insider Transactions at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 10,000 shares of Tarsus Pharmaceuticals stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $61.55, for a total value of $615,500.00. Following the completion of the transaction, the chief executive officer owned 847,991 shares of the company’s stock, valued at $52,193,846.05. The trade was a 1.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director William J. Phd Link sold 12,500 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $62.12, for a total transaction of $776,500.00. Following the sale, the director owned 106,786 shares of the company’s stock, valued at approximately $6,633,546.32. The trade was a 10.48% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 39,850 shares of company stock worth $2,452,821. 9.64% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Parallel Advisors LLC raised its stake in Tarsus Pharmaceuticals by 139.2% during the first quarter. Parallel Advisors LLC now owns 500 shares of the company’s stock worth $35,000 after acquiring an additional 291 shares during the period. PNC Financial Services Group Inc. grew its holdings in shares of Tarsus Pharmaceuticals by 367.1% during the first quarter. PNC Financial Services Group Inc. now owns 710 shares of the company’s stock valued at $50,000 after purchasing an additional 558 shares during the last quarter. Comerica Bank grew its holdings in shares of Tarsus Pharmaceuticals by 470.0% during the fourth quarter. Comerica Bank now owns 855 shares of the company’s stock valued at $70,000 after purchasing an additional 705 shares during the last quarter. Truvestments Capital LLC raised its position in shares of Tarsus Pharmaceuticals by 106.1% during the 4th quarter. Truvestments Capital LLC now owns 909 shares of the company’s stock worth $74,000 after purchasing an additional 468 shares during the period. Finally, Rockefeller Capital Management L.P. lifted its holdings in shares of Tarsus Pharmaceuticals by 15.5% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock worth $105,000 after purchasing an additional 172 shares during the last quarter. 90.01% of the stock is owned by institutional investors and hedge funds.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.